TARIS Biomedical has partnered with Bristol-Myers Squibb to undertake a Phase lb clinical trial of TAR-200 (GemRIS) in combination with Opdivo (nivolumab) in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for radical cystectomy.

The trial will examine the safety, tolerability, and preliminary efficacy of TAR-200 and Opdivo combination to treat MIBC.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Bladder cancer is estimated to affect more than 2.7 million patients worldwide.

The disease is one of the most expensive types of cancers to treat on a per-patient lifetime basis. With fewer options for treatment, bladder cancer often may metastasise and lead to death.

TARIS Biomedical president and CEO Purnanand Sarma said: “This is the first study evaluating the potential benefits of combining TAR-200 with a systemically administered immune checkpoint inhibitor.

“MIBC is a potentially lethal disease with high unmet clinical need.”

“MIBC is a potentially lethal disease with high unmet clinical need.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TARIS has been developing the TAR-200 product to release the chemotherapeutic agent gemcitabine continuously in the bladder over seven days.

The company’s TARIS System is designed to continuously release drugs in the bladder over weeks to months.

Opdivo has been developed by Bristol-Myers Squibb to harness the patient body’s own immune system to help restore anti-tumour immune response to fight cancer.

The programmed death-1 (PD-1) immune checkpoint inhibitor has already become an important treatment option across multiple cancers.

In addition to the latest clinical trial collaboration, Bristol-Myers Squibb has made an equity investment in TARIS.